LHLaura Heathers

Laura Heathers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Heathers has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PD GENEration: An International Parkinson’s Disease Genetic Research Study

    by Kamalini Ghosh Galvelis, Allison A. Dilliott, Megan Dini, Rebeca De León, Max Thom, Ignacio Azcarate, Nicola Bothwick, Lark Caboy, Anny Coral-Zambrano, Kirby Doshier, et al.

    Background: PD GENEration ( NCT04057794 , NCT04994015 ), sponsored by the Parkinson’s Foundation in partnership with Aligning Science Across Parkinson’s (ASAP) through the Global Parkinson’s Genetics Program (GP2), is an international, observational, clinical research study that offers genetic testing and counseling to people living with Parkinson’s disease (PwP) at no cost. PD GENEration has aimed to empower PwP and their clinicians with knowledge of their genetic status, to accelerate recruitment into precision medicine trials, and to advance research through data sharing. Since its launch in 2019, the study has expanded to enroll over 32,000 PwP (as of March 31, 2026), from 10 countries across North, Central, and South America, the Caribbean, and Israel. Methods: Over the course of 6 years, PD GENEration has evolved to accommodate the growing scientific and research needs of the Parkinson’s community while also increasing the ability to return genetic test results to PwP at a greater scale. Participants with a diagnosis of Parkinson’s disease (PD) may enroll in-person or virtually where informed consent and blood sample collection can occur. Samples are analyzed at a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA)-certified laboratory using whole genome sequencing, with variants curated for a primary panel of seven PD-associated genes. Results are disclosed during a genetic counseling visit, where further testing is offered for two optional additional gene panels. Those who consent undergo analysis of additional genes, and results are returned during a genetic counseling visit for those that test positive for a variant. In addition to returning genetic results to PwP, a central pillar of the study design has been the open sharing of genomic data to advance discovery in PD research in partnership with ASAP and GP2. Discussion: PD GENEration applies a flexible framework, allowing for country specific considerations and the integration of multiple site models, evolving based on participant needs and the prioritization of equity and accessibility. We summarize PD GENEration’s implementation and scaling, highlight key accomplishments and lessons learned, and provide guidance for those interested in implementing large-scale clinical genetic testing studies across other diseases and therapeutic domains.


  • Open Access

    Overcoming challenges to successful recruitment of individuals at the earliest stages of disease: An example from Parkinson’s disease research

    by Bridget McMahon, Roseanne Dobkin, Maggie Kuhl, Laura Heathers, Lynell Lemon, Jessica Dimos, Ethan Brown, Kerri A. Pierz, Ken Marek

    Background/Aims The Parkinson Progression Markers Initiative (PPMI) is an international, longitudinal, observational study that acquires comprehensive clinical, imaging and genetic data, as well as cerebral spinal fluid (CSF) and blood biological samples from individuals in all stages of Parkinson’s disease (PD) to develop biomarkers that accelerate therapeutic development. The effort to enroll a large population of prodromal individuals (participants with PD biomarkers and/or early symptoms) presents an opportunity to share insights for overcoming specific challenges unique to enrollment prior to the onset of typical symptoms. Methods Paid and earned media, referral cohorts, and individual and community ambassadors were leveraged as recruitment strategies to attract and enroll a broad study population. The success of each strategy was measured as conversion to (i) informed consent, (ii) smell test completion, and (iii) identification of hyposmic individuals. Participants completed an eConsent and questionnaire online, followed by remote smell test screening for Parkinson’s risk. Participants with hyposmia were invited to complete dopamine transporter (DAT) imaging. Those who continued to meet eligibility criteria were invited to enroll in the PPMI clinical study, for comprehensive longitudinal follow-up. Results Over 1.2 million visits to the smell test website were recorded and 79,837 participants consented to remote hyposmia screening. A smell test was sent to 57,754 participants and completed by 38,419; 6,649 were identified to be hyposmic (as defined by PPMI study cutoffs). DAT imaging was completed by 1,720, with 1,120 identified as eligible for longitudinal follow-up. The greatest number of participants who consented to smell testing came from paid media and social media ads, referral networks (commercial and study partners), and the MJFF community. Overall, 14.4% of participants who completed smell testing were confirmed to be hyposmic. The highest rates of conversion from completed UPSIT to confirmed case of hyposmia occurred with promoted online search results, earned press coverage, and radio ads. Conclusion PPMI provides a useful example of overcoming challenges to enrollment of participants with biomarkers and/or early symptoms (but without typical symptoms) of disease. Important lessons from these data for this study team, and other researchers alike, are to be agile in recruitment strategies, to utilize effective participant engagement approaches, and to prioritize centralized study teams/resources to offload site burden and streamline participant experience.

  • Open Access

    Optimizing wrist-worn wearable compliance with insights from two Parkinson’s disease cohort studies

    by Marjan J. Meinders, Laura Heathers, King Chung Ho, Laura Russell, Chris Li, Bastiaan R. Bloem, William J. Marks Jr, Ritu Kapur

    Wearable technologies enable real-time, continuous, noninvasive data collection, where long-term compliance is essential. The Personalized Parkinson Project (PPP) and the Parkinson’s Progression Markers Initiative (PPMI) utilized the Verily Study Watch. Participants, including people diagnosed with Parkinson’s disease (PD), prodromal PD, and healthy controls, were instructed to wear the watch for up to 23 h daily without data displaying or reporting data back to the participant. Compliance measures and user experiences were evaluated. A centralized support model identified barriers to data collection and enabled proactive outreach. Median daily wear time was 21.9 h for PPP and 21.1–22.2 h per day for PPMI over 2 years. Participants were highly motivated contributing to PD research. These results highlight strategies for achieving strong engagement without providing individual data. This approach offers valuable insights for study designs where returning data to participants could introduce bias or affect the data integrity.


  • Open Access

    Alcohol-induced gut microbial reorganization and associated overproduction of phenylacetylglutamine promotes cardiovascular disease

    by Zhen Li, Min Gu, Aline Zaparte, Xiaoming Fu, Kala Mahen, Marko Mrdjen, Xinmin S. Li, Zhihong Yang, Jing Ma, Themis Thoudam, et al.

    The mechanism(s) underlying gut microbial metabolite (GMM) contribution towards alcohol-mediated cardiovascular disease (CVD) is unknown. Herein we observe elevation in circulating phenylacetylglutamine (PAGln), a known CVD-associated GMM, in individuals living with alcohol use disorder. In a male murine binge-on-chronic alcohol model, we confirm gut microbial reorganization, elevation in PAGln levels, and the presence of cardiovascular pathophysiology. Fecal microbiota transplantation from pair-/alcohol-fed mice into naïve male mice demonstrates the transmissibility of PAGln production and the CVD phenotype. Independent of alcohol exposure, pharmacological-mediated increases in PAGln elicits direct cardiac and vascular dysfunction. PAGln induced hypercontractility and altered calcium cycling in isolated cardiomyocytes providing evidence of improper relaxation which corresponds to elevated filling pressures observed in vivo. Furthermore, PAGln directly induces vascular endothelial cell activation through induction of oxidative stress leading to endothelial cell dysfunction. We thus reveal that the alcohol-induced microbial reorganization and resultant GMM elevation, specifically PAGln, directly contributes to CVD.


  • Open Access

    Percentile Scores for the Revised University of Pennsylvania Smell Identification Test for 16,972 Individuals 60 years of Age and Older

    by Kerri A. Pierz, Whitley Aamodt, Caroline Gochanour, Ryan Kurth, Michael C. Brumm, Christopher S. Coffey, Laura E. Heathers, Michelle Totten, Richard L. Doty, Kenneth Marek, et al.

    Background and Objectives: The University of Pennsylvania Smell Identification Test (UPSIT) is a widely employed objective measure of smell function. A revised version of this test, termed the UPSIT-R, was developed in 2020 to update certain odorants and response options. The goal of this study was to establish normative age- and sex-specific data for the UPSIT-R in a large adult cohort and to compare the resultant percentiles to those of the original UPSIT. A second study was performed to compare the relative performance of these two tests in a small cohort of persons with and without Parkinson’s disease (PD). Methods: UPSIT-R percentiles were derived separately by age (60-64, 65-69, 70-74, 75-59, and ≥80 years) and sex (male, female) categories in 16,972 volunteers who were predominantly white and non-Hispanic. Percentiles were derived statistically using an empirical distribution averaging procedure. A Bland-Altman plot was employed to visualize the level of agreement between percentiles for the UPSIT-R and UPSIT. For the second study, non-parametric statistics were employed to compare the results of those with and without PD. Results: UPSIT-R performance declined with increasing age; deficits were more pronounced in men than in women. The magnitude of the difference between the original and revised test percentile scores differed by age and sex; women had up to a 3-point improvement with the UPSIT-R whereas the oldest male age had up to a 3-point decline in percentile scores. Olfactory deficits in PD were confirmed on the UPSIT-R. Discussion: This study provides normative data clinically useful for assessing the relative degree of dysfunction in persons 60 years of age and older using the UPSIT-R. Like the traditional version of the UPSIT, this version demonstrates that smell function declines with age and is generally better in women than in men, providing a solid clinical basis for physicians to accurately determine the degree of smell dysfunction in their patients. Trial Registration Information: ClinicalTrials.gov NCT05065060


  • Open Access

    The Promise and Pitfalls of Facebook Advertising: a Genetic Counselor's Perspective

    by Jennifer Verbrugge, Malia Rumbaugh, Lola Cook, Jeanine Schulze, Mandy Miller, Laura Heathers, Vanessa Arnedo, Maggie McGuire Kuhl, Tatiana Foroud

    Facebook advertising is a powerful tool for increasing the outreach and recruitment of research participants. We describe our experience as genetic counselors within the context of an internet-based research study, recruiting subjects for a Parkinson disease (PD) biomarker study.